ATE158282T1 - Kondensierte benzeoxyessigsäurederivate - Google Patents
Kondensierte benzeoxyessigsäurederivateInfo
- Publication number
- ATE158282T1 ATE158282T1 AT92121898T AT92121898T ATE158282T1 AT E158282 T1 ATE158282 T1 AT E158282T1 AT 92121898 T AT92121898 T AT 92121898T AT 92121898 T AT92121898 T AT 92121898T AT E158282 T1 ATE158282 T1 AT E158282T1
- Authority
- AT
- Austria
- Prior art keywords
- chem
- alkyl
- benzeoxyacetic
- condensed
- acid derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3360502A JPH05178832A (ja) | 1991-12-27 | 1991-12-27 | 縮合ベンゼンオキシ酢酸誘導体 |
JP4209587A JPH0725854A (ja) | 1992-07-14 | 1992-07-14 | 縮合ベンゼンオキシ酢酸誘導体 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE158282T1 true ATE158282T1 (de) | 1997-10-15 |
Family
ID=26517547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT92121898T ATE158282T1 (de) | 1991-12-27 | 1992-12-23 | Kondensierte benzeoxyessigsäurederivate |
Country Status (11)
Country | Link |
---|---|
US (4) | US5389666A (de) |
EP (1) | EP0548949B1 (de) |
JP (1) | JP3419009B2 (de) |
KR (1) | KR0148389B1 (de) |
AT (1) | ATE158282T1 (de) |
CA (1) | CA2085844A1 (de) |
DE (1) | DE69222280T2 (de) |
DK (1) | DK0548949T5 (de) |
ES (1) | ES2108076T3 (de) |
GR (1) | GR3024771T3 (de) |
TW (1) | TW221291B (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2085844A1 (en) * | 1991-12-27 | 1993-06-28 | Nobuyuki Hamanaka | Fused benzeneoxyacetic acid derivatives |
DE4330959A1 (de) * | 1993-09-09 | 1995-03-16 | Schering Ag | Neue Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
IT1265209B1 (it) * | 1993-11-22 | 1996-10-31 | Pierrel Spa | Difenilimidazoli utili nel trattamento di dislipidemia, arteriosclerosi e malattie coronariche procedimento per la loro |
US6117910A (en) * | 1994-12-13 | 2000-09-12 | Smithkline Beecham Corporation | Bicyclic fibrinogen antagonists |
CN1092639C (zh) | 1995-01-06 | 2002-10-16 | 东丽株式会社 | 苯稠合杂环衍生物及其用途 |
US6407096B1 (en) * | 1998-08-04 | 2002-06-18 | Toray Industries, Inc. | Benzene fused heterocyclic derivatives having thromboxane A2 receptor antagonistic activity and prostaglandin I2 Agonistic activity and application thereof |
US6781288B2 (en) * | 1999-01-27 | 2004-08-24 | Bae Systems Information And Electronic Systems Integration Inc. | Ultra-low frequency acoustic transducer |
AU5249200A (en) * | 1999-06-21 | 2001-01-09 | Fujisawa Pharmaceutical Co., Ltd. | Remedies for skin ulcer |
JP2001131151A (ja) * | 1999-11-02 | 2001-05-15 | Shionogi & Co Ltd | オレフィン誘導体の新規用途 |
US8124625B2 (en) | 2001-09-14 | 2012-02-28 | Shionogi & Co., Ltd. | Method of enhancing the expression of apolipoprotein AI using olefin derivatives |
DK1482931T3 (da) * | 2002-03-05 | 2011-12-19 | Transtech Pharma Inc | Mono- og bicycliske azolderivater der inhiberer interaktionen af ligander med RAGE |
FR2846328B1 (fr) * | 2002-10-23 | 2004-12-10 | Servier Lab | Nouveaux derives de l'imidazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
ZA200508300B (en) * | 2003-05-20 | 2007-03-28 | Transtech Pharma Inc | RAGE antagonists as agents to reverse amyloidosis and diseases associated therewith |
KR20220143141A (ko) * | 2008-03-18 | 2022-10-24 | 아레나 파마슈티칼스, 인크. | 프로스타시클린 (pgi2) 수용체와 관련된 장애의 치료에 유용한 상기 수용체의 조절제 |
SG171413A1 (en) | 2008-11-26 | 2011-07-28 | Arena Pharm Inc | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto |
US8940891B2 (en) | 2008-12-08 | 2015-01-27 | Arena Pharmaceuticals, Inc. | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto |
WO2011041198A1 (en) | 2009-09-30 | 2011-04-07 | Transtech Pharma, Inc. | Substituted imidazole derivatives for treatment of alzheimers disease |
EP3209291B1 (de) | 2014-10-23 | 2023-12-06 | Arena Pharmaceuticals, Inc. | Verfahren zur behandlung von leiden im zusammenhang mit dem pgi2-rezeptor |
AU2018227842B2 (en) | 2017-03-01 | 2024-05-02 | Arena Pharmaceuticals, Inc. | Compositions comprising PGI2-receptor agonists and processes for the preparation thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1108619A (en) * | 1977-08-12 | 1981-09-08 | Carl H. Ross | 4-hydroxy-2-benzimidazolinone derivatives and the preparation thereof |
US4368332A (en) * | 1979-01-05 | 1983-01-11 | National Research Development Corporation | Prostaglandins |
ZA829068B (en) * | 1980-07-01 | 1983-02-23 | Nat Res Dev | Prostaglandins |
DE3042466A1 (de) * | 1980-11-11 | 1982-06-16 | A. Nattermann & Cie GmbH, 5000 Köln | N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
FR2498382A1 (fr) * | 1981-01-16 | 1982-07-23 | Commissariat Energie Atomique | Connecteur electrique |
JPS57150667A (en) * | 1981-02-12 | 1982-09-17 | Wellcome Found | Antithrombotic |
US4492708A (en) * | 1982-09-27 | 1985-01-08 | Eli Lilly And Company | Antiviral benzimidazoles |
DE3504677A1 (de) * | 1985-02-12 | 1986-08-14 | A. Nattermann & Cie GmbH, 5000 Köln | Neue imidazol-2-yloxyalkansaeuren und ihre derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
CA2003283A1 (en) * | 1988-12-05 | 1990-06-05 | C. Anne Higley | Imidazoles for the treatment of atherosclerosis |
US5011851A (en) * | 1990-02-13 | 1991-04-30 | Bristol-Myers Squibb Co. | Imidazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith |
CA2036192A1 (en) * | 1990-02-13 | 1991-08-14 | Nicholas Meanwell | Heterocyclic carboxylic acids and esters |
US4956379A (en) * | 1990-02-13 | 1990-09-11 | Bristol-Myers Squibb Company | Pyrazole carboxylic acids and esters and inhibition of blood platelet aggregation therewith |
CA2085844A1 (en) * | 1991-12-27 | 1993-06-28 | Nobuyuki Hamanaka | Fused benzeneoxyacetic acid derivatives |
JP2556418B2 (ja) * | 1992-07-14 | 1996-11-20 | 大光炉材株式会社 | 不定形耐火材 |
-
1992
- 1992-12-18 CA CA002085844A patent/CA2085844A1/en not_active Abandoned
- 1992-12-22 TW TW081110276A patent/TW221291B/zh active
- 1992-12-23 EP EP92121898A patent/EP0548949B1/de not_active Expired - Lifetime
- 1992-12-23 DK DK92121898T patent/DK0548949T5/da active
- 1992-12-23 ES ES92121898T patent/ES2108076T3/es not_active Expired - Lifetime
- 1992-12-23 AT AT92121898T patent/ATE158282T1/de not_active IP Right Cessation
- 1992-12-23 DE DE69222280T patent/DE69222280T2/de not_active Expired - Fee Related
- 1992-12-28 US US07/997,492 patent/US5389666A/en not_active Expired - Fee Related
- 1992-12-28 KR KR1019920025744A patent/KR0148389B1/ko not_active IP Right Cessation
- 1992-12-28 JP JP36060892A patent/JP3419009B2/ja not_active Expired - Fee Related
-
1994
- 1994-11-03 US US08/334,395 patent/US5589496A/en not_active Expired - Fee Related
-
1996
- 1996-09-27 US US08/722,456 patent/US5849919A/en not_active Expired - Fee Related
-
1997
- 1997-09-18 GR GR970402174T patent/GR3024771T3/el unknown
-
1998
- 1998-10-07 US US09/168,424 patent/US5962439A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR0148389B1 (ko) | 1998-11-02 |
EP0548949B1 (de) | 1997-09-17 |
US5589496A (en) | 1996-12-31 |
DE69222280D1 (de) | 1997-10-23 |
US5849919A (en) | 1998-12-15 |
US5962439A (en) | 1999-10-05 |
EP0548949A2 (de) | 1993-06-30 |
US5389666A (en) | 1995-02-14 |
GR3024771T3 (en) | 1997-12-31 |
DE69222280T2 (de) | 1998-03-05 |
TW221291B (de) | 1994-02-21 |
EP0548949A3 (en) | 1993-10-06 |
DK0548949T5 (da) | 1998-11-23 |
CA2085844A1 (en) | 1993-06-28 |
ES2108076T3 (es) | 1997-12-16 |
JPH07145057A (ja) | 1995-06-06 |
JP3419009B2 (ja) | 2003-06-23 |
DK0548949T3 (da) | 1998-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69222280D1 (de) | Kondensierte Benzeoxyessigsäurederivate | |
AU7930887A (en) | Phenylpyrazolecarboxylic acid derivatives, their preparation, and their use as plant-growth regulators and safeners | |
IL110703A0 (en) | Intermediates to 4-benzoyl isoxazole derivatives | |
FI102535B1 (fi) | Menetelmä valmistaa farmaseuttisesti käyttökelpoisia 1,3,5-trisubstituoituja pyratsolijohdannaisia | |
DK0850926T3 (da) | Difluorprostaglandinderivater og deres anvendelse | |
ES2103989T3 (es) | Derivados de acido fenoxiacetico y composiciones farmaceuticas que los contienen. | |
OA09391A (en) | "Isoxazole derivatives". | |
FI103508B1 (fi) | Menetelmä anti-inflammatorisen aktiivisuuden omaavien 2-substituoitujen tiatsolidinonien, oksatsolidinonien ja imidatsolidinonien 3,5-di-tert.butyyli-4-hydroksifenyylimetyleenijohdannaisten valmistamiseksi | |
FI893467A (fi) | Menetelmä lääkeaineena käyttökelpoisten 4-oksokinoliini-3-karboksyylihapon johdannaisten valmistamiseksi | |
GR3020885T3 (en) | Fused benzeneoxyacetic acid derivatives as PGl2 receptor agonists | |
MX9606305A (es) | Productos de proteccion de cultivos. | |
NZ334701A (en) | Dihydropyrones and use in treating retrovirus infections and diseases | |
FI881104A (fi) | Menetelmä antidiabeettisina aineina käytettävien bentsoksatsiinijohdannaisten valmistamiseksi | |
DE69204908T2 (de) | 2-Hydroxy-2-phenylethylaminderivate als Beta-3-adrenoceptor Agonisten. | |
DK0451538T3 (da) | Anvendelse af pyridoindolderivater til behandling af iskæmiske lidelser | |
NO911149L (no) | Fremgangsmaate for fremstilling av merkaptan- og merkaptoacyl-derivater. | |
DE69203194D1 (de) | Thiazolidine-2,4-dione für die Behandlung der Hypertonie. | |
ATE71364T1 (de) | Fluor enthaltende vitamin-d2-derivate. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
REN | Ceased due to non-payment of the annual fee |